Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular...

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today...

NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting - First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL - Early data demonstrates promising efficacy with a predictable and...